Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer

Archive ouverte

Remmers, Sebastiaan | Bangma, Chris, H | Godtman, Rebecka, A | Carlsson, Sigrid, V | Auvinen, Anssi | Tammela, Teuvo L.J. | Denis, Louis, J | Nelen, Vera | Villers, Arnauld | Rebillard, Xavier | Kwiatkowski, Maciej | Recker, Franz | Wyler, Stephen | Zappa, Marco | Puliti, Donella | Gorini, Giuseppe | Paez, Alvaro | Lujan, Marcos | Nieboer, Daan | Schröder, Fritz, H | Roobol, Monique, J

Edité par CCSD ; Elsevier -

International audience. Background: The European Association of Urology guidelines recommend a risk-based strategy for prostate cancer screening based on the first prostate-specific antigen (PSA) level and age. Objective: To analyze the impact of the first PSA level on prostate cancer (PCa) detection and PCa-specific mortality (PCSM) in a population-based screening trial (repeat screening every 2-4 yr). Design, setting, and participants: We evaluated 25 589 men aged 55-59 yr, 16 898 men aged 60-64 yr, and 12 936 men aged 65-69 yr who attended at least one screening visit in the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial (screening arm: repeat PSA testing every 2-4 yr and biopsy in cases with elevated PSA; control arm: no active screening offered) during 16-yr follow-up (FU). Outcome measurements and statistical analysis: We assessed the actuarial probability for any PCa and for clinically significant (cs)PCa (Gleason !7). Cox proportional-hazards regression was performed to assess whether the association between baseline PSA and

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion